Saxenda is a new drug approved by the FDA as an obesity treatment in December 2014. The developer of new anti-obesity drug – Saxenda is a multinational pharmaceutical company Novo Nordisk.
Just two months after Saxenda approval in the USA, this drug was approved as an obesity treatment in Canada, and after three months – in the EU. Despite the fact that new weight loss drug – Saxenda has already been approved in the Europe, USA and Canada, today one can buy Saxenda only in the USA.
Novo Nordisk announced the launch of Saxenda sales in late April 2015. In the next few months, the start of Saxenda sales in Canada and EU member states, as well as Saxenda approval for the obesity treatment in other regions of the world can be announced.
Over the past 3 years, a few new weight loss drugs were approved in the USA, such as Contrave, Belviq and Qsymia. However, unlike these new anti-obesity drugs used for oral anti-obesity therapy, Saxenda is produced in solution for subcutaneous injections.
Since April 22, 2015, one can buy multi-dose prefilled pens containing 3ml of Saxenda solution at the US pharmacies. Each milliliter of Saxenda solution contains 6mg of active substance Liraglutide.
Thus, the dosage of active ingredient Liraglutide in a multi-dose pen is 18mg.
Each pre-filled syringe-pen has a convenient dosing device, which allows administering single doses:
• Saxenda (Liraglutide) 0.6mg
• Saxenda (Liraglutide) 1.2mg
• Saxenda (Liraglutide) 1.8mg
• Saxenda (Liraglutide) 2.4mg
• Saxenda (Liraglutide) 3.0mg
How does Saxenda work?
An exact mechanism of Saxenda action is not known. The developers of Saxenda drug assume that active ingredient Liraglutide stimulates the areas of the brain that regulate hunger and saturation.
Affecting the brain functions, Liraglutide decreases appetite and helps to increase saturation even after consuming a small amount of food.
The advantage of Liraglutide injectable drug over oral anorectics is that it significantly reduces the risk of type 2 diabetes.
Analysis of clinical trials has demonstrated that in regular use of Saxenda (Liraglutide) injectable anti-obesity drug within 3 months, the risk of type 2 diabetes decreases by approximately 80%.
It should be noted that Liraglutide anorectic agent is not similar to amphetamine-like anorectic, Phentermine. Therefore, mechanism of action and side effects of Saxenda (Liraglutide) differ from the mechanism of action and side effects of Phentermine-containing drugs.
Information on other features of innovative Saxenda anorectic you can find in the next reviews. If you are already using Saxenda, you can leave your review about this weight loss drug right now.